Provexis PLC (GB:PXS)
LSE:PXS
Want to see GB:PXS full AI Analyst Report?
PXS Stock Chart & Stats
0.71 p
0.02 p(3.46%)
At close: 4:00 PM EST
0.71 p
0.02 p(3.46%)
Day’s Range― - ―
52-Week Range0.45 p - 1.55 p
Previous CloseN/A
Volume299.72K
Average Volume (3M)426.62K
Market Cap
£22.29M
Enterprise Value21.76M
Total Cash (Recent Filing)£708.09K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta0.36
Next Earnings
Sep 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding2,345,891,400
10 Day Avg. Volume0
30 Day Avg. Volume426,617
Financial Highlights & Ratios
PEG Ratio0.68
Price to Book (P/B)7.92
Price to Sales (P/S)7.95
P/FCF Ratio-30.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero reported debt materially reduces refinancing and interest-rate risk, giving management flexibility to pursue licensing deals, R&D or selective commercial investments over the next 2-6 months without near-term leverage constraints. This durability supports survival while revenues scale.
Accelerating Revenue GrowthSustained acceleration from a small base indicates improving commercial traction with partners and successful product/ingredient rollouts. If these trends persist, they can underpin future royalty and ingredient sales growth, improving operating leverage and long-term revenue visibility.
IP/licensing-focused Business ModelA B2B licensing model leverages scalable intellectual property rather than capital-intensive manufacturing, enabling margins to improve as partners scale products. Durable partner-based revenue streams (royalties, milestones) reduce the need for large fixed-cost investment over time.
Bears Say
Persistent Negative Cash FlowConsistent negative operating and free cash flow requires ongoing funding and raises dilution or financing risk if losses persist. Over a multi-month horizon, continued cash burn can constrain commercial investment and force unfavorable financing decisions that weaken strategic optionality.
Ongoing Losses And Weak MarginsDeeply negative margins signal structural profitability issues: until ingredient sales or royalties reach scale, operating leverage remains negative. Persistent losses suppress retained earnings and limit reinvestment capacity, prolonging reliance on external capital for growth.
Very Small Scale And Weak ReturnsTiny headcount and modest equity imply limited internal capacity to commercialise multiple partnerships simultaneously. Negative ROE reflects losses and low scalability today; this concentrated, small operating base increases execution risk as partner deals must succeed to materially change fundamentals.
Provexis News
PXS FAQ
What was Provexis PLC’s price range in the past 12 months?
Provexis PLC lowest share price was 0.45 p and its highest was 1.55 p in the past 12 months.
What is Provexis PLC’s market cap?
Provexis PLC’s market cap is £22.29M.
When is Provexis PLC’s upcoming earnings report date?
Provexis PLC’s upcoming earnings report date is Sep 25, 2026 which is in 127 days.
How were Provexis PLC’s earnings last quarter?
Currently, no data Available
Is Provexis PLC overvalued?
According to Wall Street analysts Provexis PLC’s price is currently Overvalued.
Does Provexis PLC pay dividends?
Provexis PLC does not currently pay dividends.
What is Provexis PLC’s EPS estimate?
Provexis PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Provexis PLC have?
Provexis PLC has 2,345,891,400 shares outstanding.
What happened to Provexis PLC’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Provexis PLC?
Currently, no hedge funds are holding shares in GB:PXS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Provexis PLC
Provexis plc, together with its subsidiaries, develops, licenses, and markets functional foods, medical foods, and dietary supplements worldwide. Its products include Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke. The company's syrup and powder versions of Fruitflow are used in foods, beverages, and dietary supplement formats. It also offers Fruitflow + Omega-3, a supplement in capsule form that supports healthy blood flow and normal heart function. Provexis plc has a collaboration agreement with By-Health Co., Ltd. The company offers its products through retail stores, as well as online. Provexis plc was founded in 1999 and is based in Reading, the United Kingdom.